Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

LigoCyte and Biogen Idec Ally to Develop Anti-CD103 Drugs

  • LigoCyte Pharmaceuticals inked a partnership with Biogen Idec to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases.

    CD103 is a alphaE-beta7 integrin that has been implicated in the activation, homing, and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

    LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for codevelopment, copromotion, and sharing of profits resulting from commercialized products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »